))
Unresectable vs. Resectable Thyroid Cancer (Pt. 1)
Manage episode 489214981 series 3586605
Content provided by TIRO, THANC Foundation, TIRO, and THANC Foundation. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TIRO, THANC Foundation, TIRO, and THANC Foundation or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
What makes a thyroid tumor truly unresectable? In this episode, Dr. Dana Hartl speaks with Dr. Mark Zafereo about how molecular testing and targeted neoadjuvant therapies are redefining surgical eligibility for patients with anaplastic thyroid cancer. Listen in as they explore the evolving role of BRAF/MEK inhibitors, imaging strategies, and real-world decision-making in complex cases.
13 episodes
Share
